Clinical Trial of Selumetinib

Posted on: January 10, 2017 by: webmaster

A phase I clinical trial of Selumetinib has shown some early promising results in children diagnosed with NF1. read more at “New Drug Shrinks Pediatric Tumors“.

Donate Now

Your donation helps ensure that the most promising projects are thoroughly explored and funded. View our donation page for all options or donate now using the Donate link below. The NFCA is a nonprofit organization under IRS Code Section 501 (c)(3), Federal Tax ID 25-1763156.

SO THAT WE MAY PROPERLY CREDIT/RECORD YOUR DONATION, PLEASE SELECT AN OPTION UNDER "USE THIS DONATION FOR". ON THE FOLLOWING PAGE, UNDER "WRITE A NOTE", LET US KNOW THE INDIVIDUAL BEING HONORED/MEMORIALIZED, THE SPECIFIC EVENT INFORMATION, AND/OR GENERAL ACKNOWLEDGEMENT INFORMATION.